Scientists find immune drug that could halt skin cancer’s deadly spread
SMRTR summary
Scientists tested the immune drug pembrolizumab on 293 patients with Merkel cell carcinoma, a rare but deadly skin cancer, after tumor removal surgery. While the treatment didn't significantly reduce overall cancer recurrence, it cut the risk of cancer spreading to distant organs by 42%, offering hope for patients facing this aggressive disease.
SMRTR provides this summary for quick context. The original article belongs to Science Daily.
Read the original article